{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:55:44Z","timestamp":1790319344159,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"DOI":"10.1093\/cvr\/cvt006","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T06:02:05Z","timestamp":1358920925000},"page":"145-154","source":"Crossref","is-referenced-by-count":100,"title":["The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation"],"prefix":"10.1093","volume":"98","author":[{"given":"Erich","family":"Wettwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Endig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiia","family":"Rozmaritsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Matschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pourrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fedida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Knaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Ravens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,1,22]]},"reference":[{"key":"key\n\t\t\t\t20170523020352_CVT006C1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170523020352_CVT006C2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/europace\/eun193","article-title":"Role of potassium currents in cardiac arrhythmias","volume":"10","author":"Ravens","year":"2008","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170523020352_CVT006C3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1540-8167.2005.50028.x","article-title":"The mechanism of atrial antiarrhythmic action of RSD1235","volume":"16","author":"Fedida","year":"2005","journal-title":"J Cardiovasc Electrophysiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C4","first-page":"115","article-title":"Classification of antidysrhythmic drugs","volume":"1","author":"Vaughan Williams","year":"1975","journal-title":"Pharmacol Ther B"},{"key":"key\n\t\t\t\t20170523020352_CVT006C5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.704890","article-title":"Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine","volume":"116","author":"Burashnikov","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020352_CVT006C6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.104.506857","article-title":"Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation","volume":"112","author":"Gaborit","year":"2005","journal-title":"Circulation"},{"issue":"Pt 1","key":"key\n\t\t\t\t20170523020352_CVT006C7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1113\/jphysiol.1996.sp021194","article-title":"Differences between outward currents of human atrial and subepicardial ventricular myocytes","volume":"491","author":"Amos","year":"1996","journal-title":"J Physiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1540-8167.2003.03006.x","article-title":"Blockade of the inward rectifying potassium current terminates ventricular fibrillation in the guinea pig heart","volume":"14","author":"Warren","year":"2003","journal-title":"J Cardiovasc Electrophysiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FJC.0b013e31816c4325","article-title":"Inward rectifier potassium currents as a target for atrial fibrillation therapy","volume":"52","author":"Ehrlich","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C10","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1161\/CIRCULATIONAHA.105.575332","article-title":"The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation","volume":"112","author":"Dobrev","year":"2005","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020352_CVT006C11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FJC.0b013e3180547553","article-title":"The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans","volume":"50","author":"Dorian","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/13543784.16.4.519","article-title":"Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent","volume":"16","author":"Fedida","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t20170523020352_CVT006C13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacc.2010.07.046","article-title":"A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation","volume":"57","author":"Camm","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCEP.109.870204","article-title":"Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial","volume":"2","author":"Kowey","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C15","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.107.723866","article-title":"Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial","volume":"117","author":"Roy","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020352_CVT006C16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCEP.111.968305","article-title":"Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol","volume":"5","author":"Burashnikov","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.hrthm.2011.10.021","article-title":"Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations","volume":"9","author":"Sicouri","year":"2012","journal-title":"Heart Rhythm"},{"key":"key\n\t\t\t\t20170523020352_CVT006C18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/01.RES.85.5.428","article-title":"Atrial L-type Ca2+ currents and human atrial fibrillation","volume":"85","author":"Van Wagoner","year":"1999","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20170523020352_CVT006C19","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/01.CIR.0000145155.60288.71","article-title":"Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation","volume":"110","author":"Wettwer","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020352_CVT006C20","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.92.7.1954","article-title":"Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats","volume":"92","author":"Wijffels","year":"1995","journal-title":"Circulation"},{"issue":"Suppl.1","key":"key\n\t\t\t\t20170523020352_CVT006C21","first-page":"400","article-title":"Effects of the novel antiarrhythmic agent vernakalant (RSD 1235) on human atrial action potentials in chronic atrial fibrillation","volume":"28","author":"Wettwer","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170523020352_CVT006C22","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/bjp.2008.209","article-title":"Pathology-specific effects of the I(Kur)\/I(to)\/I(K,ACh) blocker AVE0118 on ion channels in human chronic atrial fibrillation","volume":"154","author":"Christ","year":"2008","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/0091270008325148","article-title":"Pharmacokinetics of the Novel Atrial-Selective Antiarrhythmic Agent Vernakalant Hydrochloride Injection (RSD1235): Influence of CYP2D6 Expression and Other Factors","volume":"49","author":"Mao","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20170523020352_CVT006C24","first-page":"61","article-title":"Late sodium current as a promising antiarrhythmic drug target for treatment of atrial fibrillation?","volume":"383","author":"Toussaint","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00005344-199103000-00018","article-title":"Effects of the new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters","volume":"17","author":"Wettwer","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C26","first-page":"460","article-title":"Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles","volume":"270","author":"Ohler","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20170523020352_CVT006C27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00210-005-1063-5","article-title":"Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of I(Ca,L)","volume":"371","author":"Christ","year":"2005","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C28","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1161\/hc4601.099466","article-title":"Molecular basis of downregulation of G-protein-coupled inward rectifying K+ current (IK,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials","volume":"104","author":"Dobrev","year":"2001","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020352_CVT006C29","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0008-6363(99)00034-6","article-title":"Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model","volume":"42","author":"Courtemanche","year":"1999","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t20170523020352_CVT006C30","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.106.630905","article-title":"AVE0118, blocker of the transient outward current (Ito) and ultrarapid delayed rectifier current (IKur), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat","volume":"114","author":"de Haan","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170523020352_CVT006C31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cardiores.2006.11.024","article-title":"Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+\/Ca2+-exchange","volume":"73","author":"Schotten","year":"2007","journal-title":"Cardiovasc Res"},{"issue":"Pt 2","key":"key\n\t\t\t\t20170523020352_CVT006C32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1469-7793.2000.t01-1-00285.x","article-title":"Molecular basis of functional voltage-gated K+ channel diversity in the mammalian myocardium","volume":"525","author":"Nerbonne","year":"2000","journal-title":"J Physiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C33","doi-asserted-by":"crossref","first-page":"H1278","DOI":"10.1152\/ajpheart.00777.2005","article-title":"Specific serine proteases selectively damage KCNH2 (hERG1) potassium channels and I(Kr)","volume":"290","author":"Rajamani","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0008-6363(99)00178-9","article-title":"Ionic mechanisms of electrical remodeling in human atrial fibrillation","volume":"44","author":"Bosch","year":"1999","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t20170523020352_CVT006C35","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jacc.2009.12.055","article-title":"Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium","volume":"55","author":"Sossalla","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C36","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cardiores.2006.01.026","article-title":"RSD1235 blocks late I(Na) and suppresses early afterdepolarizations and torsades de pointes induced by class III agents","volume":"70","author":"Orth","year":"2006","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t20170523020352_CVT006C37","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1124\/mol.107.039388","article-title":"The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels","volume":"72","author":"Eldstrom","year":"2007","journal-title":"Mol Pharmacol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C38","first-page":"H2157","article-title":"Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods","volume":"270","author":"Yue","year":"1996","journal-title":"Am J Physiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cardiores.2005.02.019","article-title":"Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs","volume":"67","author":"Duytschaever","year":"2005","journal-title":"Cardiovasc Res"},{"key":"key\n\t\t\t\t20170523020352_CVT006C40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00210-009-0452-6","article-title":"Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation","volume":"381","author":"Voigt","year":"2010","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00395-003-0409-8","article-title":"Remodeling of cardiomyocyte ion channels in human atrial fibrillation","volume":"98","author":"Dobrev","year":"2003","journal-title":"Basic Res Cardiol"},{"key":"key\n\t\t\t\t20170523020352_CVT006C42","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/01.CIR.103.5.691","article-title":"Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation","volume":"103","author":"Schotten","year":"2001","journal-title":"Circulation"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/98\/1\/145\/17394099\/cvt006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T01:54:13Z","timestamp":1595296453000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-lookup\/doi\/10.1093\/cvr\/cvt006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,22]]},"published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvt006","relation":{},"ISSN":["1755-3245","0008-6363"],"issn-type":[{"value":"1755-3245","type":"electronic"},{"value":"0008-6363","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1,22]]}}}